Wolverine Stack: What the "Wolverine Peptide" Is, What Is in It, and the Evidence

Every figure is an all-in monthly price covering the medication, physician review, refill management and shipping. There is no separate membership fee. Current pricing always lives on each product page.

There is no single molecule called the Wolverine peptide. The phrase grew up in online fitness and recovery communities as a nickname for the BPC-157 and TB-500 pairing, borrowing a comic-book character known for healing. It does not appear in any journal, on any pharmacy label or in any FDA document. When someone searches "wolverine peptide," "wolverine stack" or "wolverine peptide stack," they mean the same two compounds.

The nickname implies something the research does not show. No study in humans has measured whether either peptide, or the pair, speeds healing of an injury. The name is marketing; the useful questions are what each component is, what the animal and cell work describes, and what a prescription vial actually contains.

Neither is a hormone or a steroid. Neither binds an androgen receptor, suppresses your own hormone production or adds muscle directly, and nothing in either literature describes a painkilling mechanism. The full references are at what is BPC-157 and what is TB-500.

TB-500 is not the same as thymosin beta-4

This detail changes how to read the research. Thymosin beta-4 is the full 43-amino-acid protein. TB-500 as compounded today is a seven-amino-acid piece of it, the actin-binding region, with an acetyl group on the first amino acid. Most of the published thymosin beta-4 work, and every human trial, used the full protein. That the fragment does what the parent does is a reasonable inference from the shared sequence, not something that has been tested in people.

Tissue repair runs in overlapping phases, and the two peptides are described in different ones.

Tendons and ligaments have a poor blood supply, which is a large part of why they heal slowly, and that is the problem BPC-157 is described around. Repair cells reaching the site is a different problem, and that is TB-500's. Clinicians pair them because the described mechanisms are complementary, and one vial means one injection, one schedule and one refill. That is a coherent mechanistic argument, not a trial result.

The vial arrives as a ready-to-use solution at a stated concentration, compounded by the pharmacy, so there is no powder to mix and no bacteriostatic water to add. That is a real difference from research-use powders, where the buyer reconstitutes two vials and does two sets of arithmetic. The Pen's ratio of the two peptides differs from the vial's, which is why its directions are separate; it removes the draw step, and neither format is clinically better. The Pen is sold into every state Pepti serves except Alabama. More on formats is in vial vs pen.

How it is dosed

Into the fat layer, not the muscle, with abdomen and thigh the usual sites, rotated. Five days on and two off is a common convention for recovery peptides, easy to keep, and it maps the vial's 20 doses onto four working weeks. Some prescribers direct injection near the affected area and others do not, because the mechanisms described are systemic. You do not need to calculate anything: your physician sets your directions after reviewing your intake, and they are printed on the vial. Refills run every 28 days, one vial per fill. Technique is in how to inject peptides safely.

GLOW and KLOW are the Wolverine pair with additions, not alternatives to it.

Two things stand out. Both blends deliver twice as much BPC-157 and TB-500 per 0.25 mL as the two-peptide vial, because their vials hold 2 mg/mL of each rather than 1 mg/mL. And GHK-Cu is the largest component of both blends by mass, which is why they are positioned toward skin and connective tissue as much as toward injury. For a single tendon or ligament problem with nothing else in the picture, the two-peptide vial is the simpler prescription with fewer variables. The full comparison is in KLOW vs GLOW, with references at what is GLOW and what is KLOW.

As of the FDA pages checked in September 2026:

An advisory committee vote is a recommendation, not a decision. Neither peptide is banned, both remain legal to prescribe and dispense as compounded medications, and neither is an FDA-approved drug. Are peptides FDA approved explains the difference between not approved and not legal.

Sport

Both are prohibited at all times under the World Anti-Doping Agency's 2026 Prohibited List: BPC-157 under S0, non-approved substances, and TB-500 under S2.3 as a thymosin beta-4 derivative. A tested athlete should assume both are prohibited and say so at intake. See is BPC-157 banned.

Both components are generally described as well tolerated in the published animal work. What is reported clinically is mostly at the injection site: redness, mild soreness and occasional bruising, sometimes with early nausea, light-headedness or a brief flush. The human safety record for full-length thymosin beta-4 comes from small trials that reported no serious drug-related adverse events; there is no equivalent human dataset for the TB-500 fragment or for BPC-157 by injection. The FDA's stated concern for both is immunogenicity, an immune reaction to impurities or aggregates, which is an argument for a tested pharmacy preparation. There is no established interaction list for either, which is why the intake asks for every medication you take. Stop and contact your physician for any reaction that is severe, spreading or involves difficulty breathing.

There are no randomised controlled trials of BPC-157, TB-500 or the pair for injury in humans. BPC-157's human record is a single incomplete 2005 abstract in ulcerative colitis. TB-500 the fragment has no human data; full-length thymosin beta-4 has a volunteer safety study and phase 2 trials in skin ulcers and dry eye, none for tendon or muscle. The one study of the combination is a 2026 rat study in which the pair did not beat either peptide alone.

So the accurate framing is "described in preclinical research for each component and used clinically together," not "shown to work in people." The nickname suggests rapid healing; nothing in the literature establishes that in humans. Neither peptide replaces rehabilitation, and for tendinopathy, progressive loading under a physiotherapist has human trial evidence that neither peptide has. A complete rupture or displaced fracture is a surgical question. A provider promising a healing timeline is inventing it.

BPC-157 + TB-500 cannot be bought legitimately without a prescription. Vials sold "for research use only" arrive as powders with no pharmacy accountable for identity, purity, sterility or concentration; see research peptides vs prescription peptides. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A pharmacy compounds it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with ice packs, sterile syringes and alcohol prep pads, with your directions printed on the vial.
5. Your physician stays reachable for questions and dose changes.

Pepti prescribes BPC-157 + TB-500 in all 50 states and DC. Step-by-step pages: how to get BPC-157 + TB-500 prescribed online, how to get KLOW prescribed online, how to get BPC-157 prescribed online and how to get TB-500 prescribed online.